Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Y. Cheah, John M. Pagel, Jennifer A. Woyach, Bita Fakhri, Toby A. Eyre, Nicole Lamanna, Manish R. Patel, Alvaro Alencar, Ewa Lech-Maranda, William G. Wierda, Catherine C. Coombs, James N. Gerson, Paolo Ghia, Steven Le Gouill, David John Lewis, Suchitra Sundaram, Jonathon B. CohenIan W. Flinn, Constantine S. Tam, Minal A. Barve, Bryone Kuss, Justin Taylor, Omar Abdel-Wahab, Stephen J. Schuster, M. Lia Palomba, Katharine L. Lewis, Lindsey E. Roeker, Matthew S. Davids, Xuan Ni Tan, Timothy S. Fenske, Johan Wallin, Donald E. Tsai, Nora C. Ku, Edward Zhu, Jessica Chen, Ming Yin, Binoj Nair, Kevin Ebata, Narasimha Marella, Jennifer R. Brown, Michael Wang

Research output: Contribution to journalArticlepeer-review

96 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Agricultural and Biological Sciences